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Background: There were no sufficient reports on continuous intravenous infusion of beta-blocker in early phase of acute myocardial infarction 
(AMI)regardless of much recommendation.
Methods: Total of consecutive 26 patients underwent successful emergent coronary intervention (PCI) for first anterior AMI. All patients divided 
into two groups, Landiolol group (n=14) and control (n=12). Immediately after PCI, intravenous ultra short-acting beta-blocker Landiolol was 
administered for 24 hours (5μg/kg/min) in Landiolol group. Biochemical markers were evaluated through the first 24 hours.
Results: Peak-CK and CK-AUC (area under the blood concentration time curve) in Landiolol group were significantly lower than its in control (Peak-
CK: Landiolol vs control= 3107.0±1575.1 vs 5078.2±2748.2 U/I, p=0.0394, CK-AUC: see table). Although only one transient bradycardia was seen 
in Ladiolol group, it was solved immediately with reduction in dose. Any other adverse cardiac events were not observed among both groups.
Conclusions: Landiolol might have possibilities to inhibit an expansion of myocardial injury in AMI. This study might be recognized the first clinical 
investigation for its efficacy and safety in early phase of AMI.
